The possibility that tetracyclines may be beneficial for systemic infections both in limiting bacterial DNA release and in directly suppressing inflammation deserves further investigation, as does the possibility that pharmacological TLR9 blocking might be employed in combination with cidal drugs to minimize harmful inflammation in these types of infections. The gene discussed is TLR9; the disease is infection.